世界の転移性大腸がん治療薬市場予測2023-2029:化学療法薬、分子標的薬

【英語タイトル】Metastatic Colorectal Cancer Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが出版した調査資料(MMG23FB2203)・商品コード:MMG23FB2203
・発行会社(調査会社):Market Monitor Global
・発行日:2023年2月
・ページ数:64
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,250 ⇒換算¥494,000見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD4,225 ⇒換算¥642,200見積依頼/購入/質問フォーム
Enterprise User(閲覧人数制限なし)USD4,875 ⇒換算¥741,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の転移性大腸がん治療薬市場規模と予測を収録しています。・世界の転移性大腸がん治療薬市場:売上、2018年-2023年、2024年-2029年
・世界の転移性大腸がん治療薬市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の転移性大腸がん治療薬市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「化学療法薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

転移性大腸がん治療薬のグローバル主要企業は、Pfizer、Merck、Eli Lilly、Roche、Genentech、Bristol Myers Squibb、Bayer、Novartis、Teva、Sanofi、Regeneron Pharmaceuticals、Taiho Pharmaceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、転移性大腸がん治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の転移性大腸がん治療薬市場:タイプ別、2018年-2023年、2024年-2029年
世界の転移性大腸がん治療薬市場:タイプ別市場シェア、2022年
・化学療法薬、分子標的薬

世界の転移性大腸がん治療薬市場:用途別、2018年-2023年、2024年-2029年
世界の転移性大腸がん治療薬市場:用途別市場シェア、2022年
・病院、診療所、その他

世界の転移性大腸がん治療薬市場:地域・国別、2018年-2023年、2024年-2029年
世界の転移性大腸がん治療薬市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における転移性大腸がん治療薬のグローバル売上、2018年-2023年
・主要企業における転移性大腸がん治療薬のグローバル売上シェア、2022年
・主要企業における転移性大腸がん治療薬のグローバル販売量、2018年-2023年
・主要企業における転移性大腸がん治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Pfizer、Merck、Eli Lilly、Roche、Genentech、Bristol Myers Squibb、Bayer、Novartis、Teva、Sanofi、Regeneron Pharmaceuticals、Taiho Pharmaceutical

*************************************************************

・調査・分析レポートの概要
転移性大腸がん治療薬市場の定義
市場セグメント
世界の転移性大腸がん治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の転移性大腸がん治療薬市場規模
世界の転移性大腸がん治療薬市場規模:2022年 VS 2029年
世界の転移性大腸がん治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの転移性大腸がん治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の転移性大腸がん治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:化学療法薬、分子標的薬
転移性大腸がん治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:病院、診療所、その他
転移性大腸がん治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別転移性大腸がん治療薬市場規模 2022年と2029年
地域別転移性大腸がん治療薬売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Pfizer、Merck、Eli Lilly、Roche、Genentech、Bristol Myers Squibb、Bayer、Novartis、Teva、Sanofi、Regeneron Pharmaceuticals、Taiho Pharmaceutical

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Metastatic Colorectal Cancer Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metastatic Colorectal Cancer Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metastatic Colorectal Cancer Drug Overall Market Size
2.1 Global Metastatic Colorectal Cancer Drug Market Size: 2022 VS 2029
2.2 Global Metastatic Colorectal Cancer Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Metastatic Colorectal Cancer Drug Players in Global Market
3.2 Top Global Metastatic Colorectal Cancer Drug Companies Ranked by Revenue
3.3 Global Metastatic Colorectal Cancer Drug Revenue by Companies
3.4 Top 3 and Top 5 Metastatic Colorectal Cancer Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Metastatic Colorectal Cancer Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Metastatic Colorectal Cancer Drug Players in Global Market
3.6.1 List of Global Tier 1 Metastatic Colorectal Cancer Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Metastatic Colorectal Cancer Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Metastatic Colorectal Cancer Drug Market Size Markets, 2022 & 2029
4.1.2 Chemotherapy Drug
4.1.3 Targeted Drug
4.2 By Type – Global Metastatic Colorectal Cancer Drug Revenue & Forecasts
4.2.1 By Type – Global Metastatic Colorectal Cancer Drug Revenue, 2018-2023
4.2.2 By Type – Global Metastatic Colorectal Cancer Drug Revenue, 2024-2029
4.2.3 By Type – Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Metastatic Colorectal Cancer Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Metastatic Colorectal Cancer Drug Revenue & Forecasts
5.2.1 By Application – Global Metastatic Colorectal Cancer Drug Revenue, 2018-2023
5.2.2 By Application – Global Metastatic Colorectal Cancer Drug Revenue, 2024-2029
5.2.3 By Application – Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Metastatic Colorectal Cancer Drug Market Size, 2022 & 2029
6.2 By Region – Global Metastatic Colorectal Cancer Drug Revenue & Forecasts
6.2.1 By Region – Global Metastatic Colorectal Cancer Drug Revenue, 2018-2023
6.2.2 By Region – Global Metastatic Colorectal Cancer Drug Revenue, 2024-2029
6.2.3 By Region – Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Metastatic Colorectal Cancer Drug Revenue, 2018-2029
6.3.2 US Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.3.3 Canada Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.3.4 Mexico Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Metastatic Colorectal Cancer Drug Revenue, 2018-2029
6.4.2 Germany Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.4.3 France Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.4.4 U.K. Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.4.5 Italy Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.4.6 Russia Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.4.7 Nordic Countries Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.4.8 Benelux Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Metastatic Colorectal Cancer Drug Revenue, 2018-2029
6.5.2 China Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.5.3 Japan Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.5.4 South Korea Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.5.5 Southeast Asia Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.5.6 India Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Metastatic Colorectal Cancer Drug Revenue, 2018-2029
6.6.2 Brazil Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.6.3 Argentina Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Metastatic Colorectal Cancer Drug Revenue, 2018-2029
6.7.2 Turkey Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.7.3 Israel Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Metastatic Colorectal Cancer Drug Market Size, 2018-2029
6.7.5 UAE Metastatic Colorectal Cancer Drug Market Size, 2018-2029
7 Metastatic Colorectal Cancer Drug Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Metastatic Colorectal Cancer Drug Major Product Offerings
7.1.4 Pfizer Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Metastatic Colorectal Cancer Drug Major Product Offerings
7.2.4 Merck Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Eli Lilly
7.3.1 Eli Lilly Company Summary
7.3.2 Eli Lilly Business Overview
7.3.3 Eli Lilly Metastatic Colorectal Cancer Drug Major Product Offerings
7.3.4 Eli Lilly Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.3.5 Eli Lilly Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Metastatic Colorectal Cancer Drug Major Product Offerings
7.4.4 Roche Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 Genentech
7.5.1 Genentech Company Summary
7.5.2 Genentech Business Overview
7.5.3 Genentech Metastatic Colorectal Cancer Drug Major Product Offerings
7.5.4 Genentech Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.5.5 Genentech Key News & Latest Developments
7.6 Bristol Myers Squibb
7.6.1 Bristol Myers Squibb Company Summary
7.6.2 Bristol Myers Squibb Business Overview
7.6.3 Bristol Myers Squibb Metastatic Colorectal Cancer Drug Major Product Offerings
7.6.4 Bristol Myers Squibb Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.6.5 Bristol Myers Squibb Key News & Latest Developments
7.7 Bayer
7.7.1 Bayer Company Summary
7.7.2 Bayer Business Overview
7.7.3 Bayer Metastatic Colorectal Cancer Drug Major Product Offerings
7.7.4 Bayer Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.7.5 Bayer Key News & Latest Developments
7.8 Novartis
7.8.1 Novartis Company Summary
7.8.2 Novartis Business Overview
7.8.3 Novartis Metastatic Colorectal Cancer Drug Major Product Offerings
7.8.4 Novartis Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.8.5 Novartis Key News & Latest Developments
7.9 Teva
7.9.1 Teva Company Summary
7.9.2 Teva Business Overview
7.9.3 Teva Metastatic Colorectal Cancer Drug Major Product Offerings
7.9.4 Teva Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.9.5 Teva Key News & Latest Developments
7.10 Sanofi
7.10.1 Sanofi Company Summary
7.10.2 Sanofi Business Overview
7.10.3 Sanofi Metastatic Colorectal Cancer Drug Major Product Offerings
7.10.4 Sanofi Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.10.5 Sanofi Key News & Latest Developments
7.11 Regeneron Pharmaceuticals
7.11.1 Regeneron Pharmaceuticals Company Summary
7.11.2 Regeneron Pharmaceuticals Business Overview
7.11.3 Regeneron Pharmaceuticals Metastatic Colorectal Cancer Drug Major Product Offerings
7.11.4 Regeneron Pharmaceuticals Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.11.5 Regeneron Pharmaceuticals Key News & Latest Developments
7.12 Taiho Pharmaceutical
7.12.1 Taiho Pharmaceutical Company Summary
7.12.2 Taiho Pharmaceutical Business Overview
7.12.3 Taiho Pharmaceutical Metastatic Colorectal Cancer Drug Major Product Offerings
7.12.4 Taiho Pharmaceutical Metastatic Colorectal Cancer Drug Revenue in Global Market (2018-2023)
7.12.5 Taiho Pharmaceutical Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Metastatic Colorectal Cancer Drug Market Opportunities & Trends in Global Market
Table 2. Metastatic Colorectal Cancer Drug Market Drivers in Global Market
Table 3. Metastatic Colorectal Cancer Drug Market Restraints in Global Market
Table 4. Key Players of Metastatic Colorectal Cancer Drug in Global Market
Table 5. Top Metastatic Colorectal Cancer Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Metastatic Colorectal Cancer Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Metastatic Colorectal Cancer Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Metastatic Colorectal Cancer Drug Product Type
Table 9. List of Global Tier 1 Metastatic Colorectal Cancer Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Metastatic Colorectal Cancer Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Metastatic Colorectal Cancer Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Metastatic Colorectal Cancer Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Metastatic Colorectal Cancer Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Metastatic Colorectal Cancer Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Metastatic Colorectal Cancer Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Metastatic Colorectal Cancer Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Metastatic Colorectal Cancer Drug Product Offerings
Table 32. Pfizer Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Merck Company Summary
Table 35. Merck Metastatic Colorectal Cancer Drug Product Offerings
Table 36. Merck Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Merck Key News & Latest Developments
Table 38. Eli Lilly Company Summary
Table 39. Eli Lilly Metastatic Colorectal Cancer Drug Product Offerings
Table 40. Eli Lilly Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 41. Eli Lilly Key News & Latest Developments
Table 42. Roche Company Summary
Table 43. Roche Metastatic Colorectal Cancer Drug Product Offerings
Table 44. Roche Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Roche Key News & Latest Developments
Table 46. Genentech Company Summary
Table 47. Genentech Metastatic Colorectal Cancer Drug Product Offerings
Table 48. Genentech Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Genentech Key News & Latest Developments
Table 50. Bristol Myers Squibb Company Summary
Table 51. Bristol Myers Squibb Metastatic Colorectal Cancer Drug Product Offerings
Table 52. Bristol Myers Squibb Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 53. Bristol Myers Squibb Key News & Latest Developments
Table 54. Bayer Company Summary
Table 55. Bayer Metastatic Colorectal Cancer Drug Product Offerings
Table 56. Bayer Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Bayer Key News & Latest Developments
Table 58. Novartis Company Summary
Table 59. Novartis Metastatic Colorectal Cancer Drug Product Offerings
Table 60. Novartis Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 61. Novartis Key News & Latest Developments
Table 62. Teva Company Summary
Table 63. Teva Metastatic Colorectal Cancer Drug Product Offerings
Table 64. Teva Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 65. Teva Key News & Latest Developments
Table 66. Sanofi Company Summary
Table 67. Sanofi Metastatic Colorectal Cancer Drug Product Offerings
Table 68. Sanofi Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 69. Sanofi Key News & Latest Developments
Table 70. Regeneron Pharmaceuticals Company Summary
Table 71. Regeneron Pharmaceuticals Metastatic Colorectal Cancer Drug Product Offerings
Table 72. Regeneron Pharmaceuticals Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 73. Regeneron Pharmaceuticals Key News & Latest Developments
Table 74. Taiho Pharmaceutical Company Summary
Table 75. Taiho Pharmaceutical Metastatic Colorectal Cancer Drug Product Offerings
Table 76. Taiho Pharmaceutical Metastatic Colorectal Cancer Drug Revenue (US$, Mn) & (2018-2023)
Table 77. Taiho Pharmaceutical Key News & Latest Developments
List of Figures
Figure 1. Metastatic Colorectal Cancer Drug Segment by Type in 2022
Figure 2. Metastatic Colorectal Cancer Drug Segment by Application in 2022
Figure 3. Global Metastatic Colorectal Cancer Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Metastatic Colorectal Cancer Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Metastatic Colorectal Cancer Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Metastatic Colorectal Cancer Drug Revenue in 2022
Figure 8. By Type - Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 16. US Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 20. Germany Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 28. China Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Metastatic Colorectal Cancer Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Metastatic Colorectal Cancer Drug Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Eli Lilly Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Roche Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Genentech Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Bristol Myers Squibb Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Bayer Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Novartis Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Teva Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Sanofi Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Regeneron Pharmaceuticals Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Taiho Pharmaceutical Metastatic Colorectal Cancer Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



★調査レポート[世界の転移性大腸がん治療薬市場予測2023-2029:化学療法薬、分子標的薬] (コード:MMG23FB2203)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の転移性大腸がん治療薬市場予測2023-2029:化学療法薬、分子標的薬]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆